Sildenafil promotes dual memory effects in young rats: involvement of dopamine reuptake
Abstract
Sildenafil, a phosphodiesterase-5 inhibitor, crosses the blood–brain barrier, enhancing cGMP signaling, dopamine neurotransmission, and hippocampal plasticity—key mechanisms for learning and memory. This study aimed to (1) determine whether sildenafil influences hippocampal dopamine levels by modulating dopamine transporter (DAT) function in naïve young rats; (2) assess sildenafil-induced dopamine increases by evaluating its impact on hippocampal-dependent memories in non-aversive and aversive tasks; and (3) examine the effects of acute sildenafil administration on hippocampal synaptic plasticity. DAT function was assessed through ex-vivo dopamine reuptake analysis in the hippocampus and nucleus accumbens of rats sacrificed 2 h post-administration. Memory effects were evaluated by administering sildenafil 2 h before training in non-aversive (novel object recognition-NOR, Y-maze, Barnes maze) and aversive (step-down inhibitory avoidance, fear conditioning) tasks. To examine D3 receptor (D3R) involvement, a subset of animals received the selective D3R antagonist FAUC-365 before NOR training. Synaptic plasticity was analyzed via electrophysiology and dendritic spine density. Sildenafil reduced dopamine reuptake, likely by inhibiting DAT. It impaired NOR performance, an effect prevented by D3R antagonism, while leaving working and long-term spatial memory unaffected. Additionally, sildenafil enhanced aversive memory expression, facilitated hippocampal long-term potentiation, and…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.